Presentation Template for Biotechnology: Investor Decks, FDA Briefings, and Pipeline Presentations

Biotechnology presentations face a challenge few other industries encounter: the same core story must be credible to a molecular biologist and a fund manager sitting in adjacent chairs. A chief medical officer needs to see that the mechanism of action is sound; the investment analyst next to her needs to see that the addressable market and IP runway justify an $80M Series B. Pitching too deep loses the generalists; pitching too shallow loses the scientists who will validate your claims.

This guide covers the primary presentation formats in biotech — investor decks for pre-clinical and clinical stage companies, FDA advisory committee briefings, partnership pitch decks, and pipeline visualization — with structure guidance for each audience.

Pre-Clinical Stage Investor Presentation

Pre-clinical presentations must compensate for an absence of human data with rigorous mechanistic evidence and a compelling strategic narrative. Investors at this stage are buying the hypothesis, the team's ability to prosecute it, and the asset's competitive position.

Recommended structure for pre-clinical investor deck:

| Slide | Content | Key emphasis | |-------|---------|--------------| | 1 | Problem and patient population | Disease burden, unmet need — use prevalence and incidence data from published literature | | 2 | Mechanism of action | Clear biological rationale — visual pathway diagram, not a wall of text | | 3 | Asset overview | Molecule class, target, modality, differentiation from existing approaches | | 4 | Pre-clinical data package | In vitro and in vivo efficacy data, PK/PD profile, selectivity, safety signals | | 5 | Competitive landscape | Mechanism comparison table, stage of competing programs, why your approach wins | | 6 | Development roadmap | IND filing timeline, Phase 1 design rationale, go/no-go criteria | | 7 | IP position | Patent landscape, exclusivity window, Freedom to Operate status | | 8 | Team | Scientific founders, key hires, advisory board — credentials that validate the science | | 9 | Financials and use of proceeds | Burn rate, runway, what this round buys (IND? Phase 1 data?) | | 10 | Ask and terms | Round size, lead investor status, strategic value-adds sought |

Pre-clinical data slide discipline: Present data that an informed investor can evaluate, not data that requires a PhD to interpret. Include the statistical test and sample size. State the species for animal studies. If there is a gap between your animal model and the human disease, name it explicitly — sophisticated investors will ask, and a pre-emptive acknowledgment builds credibility rather than eroding it.

Clinical Stage (Phase 1–3) Investor Presentation

Once clinical data exists, the investor deck shifts from hypothesis to evidence. The primary question becomes: what has the drug demonstrated, and what remains to be proven?

Clinical readout slides:

For Phase 1 dose-escalation data, present the dose-response relationship clearly. Include the safety profile — dose-limiting toxicities, treatment-emergent adverse events at each cohort, and the Maximum Tolerated Dose if established. Phase 1 investors are looking for a safety profile that supports advancement, not perfection.

For Phase 2 efficacy data, present the primary endpoint against the pre-specified threshold. Include confidence intervals — never present a point estimate alone. If you used a biomarker-selected patient population, explain the selection rationale and address the generalizability question proactively.

Waterfall charts for tumor response: The waterfall chart showing percent change from baseline in tumor size is standard in oncology presentations. Use consistent sorting (greatest decrease to greatest increase, left to right). Color-code by response category (complete response, partial response, stable disease, progressive disease) using the RECIST criteria. Include a horizontal line at the 30% decrease threshold that defines partial response. Label the responder rate numerically above the chart.

FDA Advisory Committee Briefing Template

FDA advisory committee (AdCom) presentations are among the highest-stakes presentations in medicine. The committee's vote influences but does not bind the FDA, and the briefing document is public. The audience includes committee members (academic clinicians, biostatisticians, patient representatives), FDA staff, and interested parties.

Structure for sponsor's presentation at AdCom:

Background and unmet need: Contextualize the disease — current standard of care, limitations, patient outcomes under existing therapy. This section is for the patient representatives and less specialized committee members; keep the language accessible.

Clinical pharmacology summary: PK/PD, drug-drug interactions, special populations (renal/hepatic impairment, pediatric). FDA reviewers will scrutinize this. Present the dose rationale with pharmacodynamic justification.

Efficacy findings: Lead with the primary endpoint from the pivotal trial. Present the pre-specified primary analysis first, then sensitivity analyses. Be explicit about the patient population, duration of follow-up, and censoring rules. Subgroup forest plots must follow standard conventions — show the overall estimate and subgroups with consistent scaling.

Safety: Adverse events by system organ class using MedDRA coding. Present treatment-emergent adverse events (TEAEs) ≥ specified threshold in a frequency table. Serious adverse events (SAEs) with attribution. Deaths on study. Handle any unexpected findings directly — the committee will ask, and evasion is noted.

Risk-benefit synthesis: Explicitly address the risk-benefit tradeoff for the target population. FDA language: state whether the observed benefit "outweighs" the risk, not whether the drug is "safe" — absolute safety is never claimable.

Questions for the committee: Regulatory submissions to AdCom include specific questions the committee will vote on. Present your preferred framing of each question and explain why you believe the evidence supports a favorable vote.

Partnership Pitch Deck (BD/Licensing Presentations)

Partnership presentations are directed at business development executives and their scientific due diligence teams at larger pharma and biotech companies. The objective is not investment — it is a licensing deal, co-development agreement, or acquisition discussion.

Differentiation from investor decks: BD presentations spend more time on the asset's fit within the potential partner's therapeutic area strategy. Lead with a competitive intelligence slide that shows the partner's current pipeline and where your asset fills a gap or accelerates their position.

Licensing deal structure slides: Include a proposed deal structure section — upfront payment range, milestone structure tied to development events, royalty tier on net sales. Biotech companies that cannot name deal terms lose credibility in BD discussions; partners interpret the absence of specifics as either negotiation theater or lack of seriousness.

IP and regulatory package: BD partners are acquiring rights — they need to see the IP package (patents, applications, assignments), the regulatory history (pre-IND meeting minutes, IND number, any FDA correspondence), and the clinical data package in full. These go in the appendix and are provided under CDA; the main deck summarizes.

Pipeline Waterfall Chart and Regulatory Milestone Timeline

Biotech companies with multiple assets use pipeline slides to show portfolio breadth and development momentum. Two visual formats are standard:

Pipeline table format: Rows are assets, columns are development stages (Discovery → Pre-clinical → Phase 1 → Phase 2 → Phase 3 → NDA/BLA → Commercial). Shade cells to show current stage and planned advancement. Include the indication for each asset. Add a legend for partnership status (internal, partnered, out-licensed).

Regulatory milestone timeline: Gantt-style timeline with regulatory milestones as markers: IND filing, Phase 1 initiation, Phase 1 data readout, End-of-Phase-2 meeting with FDA, Phase 3 initiation, NDA/BLA filing, PDUFA date. Space milestones correctly — FDA review standard timelines (12 months for standard review, 6 months for priority review) should be accurate. Do not compress timelines to look aggressive; sophisticated investors know the FDA clock.

Scientific poster adaptation to slides: Conference scientific posters translated directly to slides are unreadable — the font is too small, the layout assumes a standing reader at close range, and the density is wrong. When adapting poster data for slides, disaggregate each figure onto its own slide, enlarge axis labels, and add a one-sentence interpretive headline above each figure that states the conclusion.

Bridging Scientists and Fund Managers in the Same Room

When presenting to a mixed room of technical and financial audiences, use a layered disclosure structure:

Lead headline: State the clinical or scientific conclusion in plain language — "The drug eliminated the tumor in 78% of treated mice at the lowest effective dose."

Supporting detail layer: Add the statistical and methodological context below the headline — "n=12 per group, Student's t-test, p=0.003 vs. vehicle control, xenograft model, dose at 10 mg/kg QD."

Appendix depth: Technical details that scientists need but fund managers do not — complete assay protocols, full statistical analysis plans, source data tables — belong in the appendix, available for diligence but not forced on the general audience.

This structure lets scientists validate claims at the supporting-detail level while keeping fund managers engaged at the headline level. The investor who asks a scientific question demonstrates sophistication — direct them to the supporting detail and the appendix without breaking the room's momentum.

Using slide-deck.io for Biotech Presentations

Biotech presentations require rapid iteration — an investor meeting booked for next Wednesday, an AdCom briefing with a 30-day FDA comment window. slide-deck.io generates the structural scaffold and placeholder slides for each format so scientific and BD teams can focus on populating the actual data rather than debating slide order.

PPTX export allows integration with medical affairs templates and regulatory submission document management systems. Generate the framework, populate with your clinical and pre-clinical data, and deliver a presentation that bridges the scientific and financial audiences without losing either.